MET and non-small cell lung carcinoma: Recent molecular subtyping of METex14 NSCLC (i.e., MET-driven, FGFR-activated, immune-activated, and bypass-activated) has provided new insights into how inter-tumoral molecular heterogeneity may determine immunotherapy response in these patients (18).